MMV371

MMV371

Translational
-
Preclinical
Janssen
Asexual blood stages
Chemoprevention
Product vision
  • Prophylaxis: long-acting injectable 

MOA
  • Prodrug; active moiety is atovaquone (selective inhibitor of cytochrome bc1 complex)

Key features
  • Prodrug of well-tolerated, marketed prophylactic drug (atovaquone)
  • Targets actively replicating parasites in the liver, bloodstream, and vector stages of infection
  • Potential partner for MMV055 in a long-acting injectable product
Challenges
  • Development of a combination product

Status
  • Preclinical development - Good Laboratory Practice intra-muscular safety studies complete

  • CMC - Good Manufacturing Practice drug product manufacture ongoing

Next milestone
  • Start of first-in-human phase I in Q3 2023
Previously
  • Discovery partnership between MMV and Calibr
  • Name: mCBE161
Project Director
  • Dr Andrew Slade